Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a National Multicenter Surveillance study

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 2, 1997, Pages 292-297

  Doern, Gary V ^a,c   Brueggemann, Angela B ^a   Pierce, Gary ^a   Holley Jr , H Preston ^b   Rauch, Alan ^b  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFACLOR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LORACARBEF; MACROLIDE; RIFAMPICIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM DETECTION; BACTERIUM ISOLATION; CHRONIC BRONCHITIS; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; OTITIS MEDIA; PRIORITY JOURNAL; SINUSITIS;

EID: 0031040061     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.2.292     Document Type: Article

References (29)

1. Barry, A. L., M. A. Pfaller, P. C. Fuchs, and R. R. Packer. 1994. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob. Agents Chemother. 38:2419-2425.
2. Bell, S. M., and D. Plowman. 1980. Mechanisms of ampicillin resistance in Haemophilus influenzae from the respiratory tract. Lancet i:279.
3. Black, S. B., H. R. Shinefield, and The Kaiser Permanente Vaccine Study Group. 1992. Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large HMO population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. Pediatr. Infect. Dis. 11:610-613.
4. Campos, J. M. 1995. Haemophilus, p. 556-565. In P. R. Murray. E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. ASM Press, Washington, D.C.
5. Clairoux, N., M. Picard, A. Brochu, N. Rousseau, P. Gourde, D. Beauchamp, T. R. Parr, Jr., M. G. Bergeron, and F. Malouin. 1992. Molecular basis of non-β-lactamase-mediated resistance to β-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada. Antimicrob. Agents Chemother. 36:1504-1513.
6. Doern, G. V. 1988. Antimicrobial resistance among isolates of Haemophilus influenzae and Branhamella catarrhalis. Clin. Microbiol. Newsl. 10:185-187.
7. Doern, G. V. 1995. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am. J. Med. 99:6B-6S.
8. Doern, G. V., J. H. Jorgensen, C. Thornsberry, D. A. Preston, T. Tubert, J. S. Redding, and L. A. Maher. 1988. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob. Agents Chemother. 32:180-185.
9. Doern, G. V., J. H. Jorgensen, C. Thornsberry, D. A. Preston, and the Haemophilus influenzae Surveillance Group. 1986. Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. Diagn. Microbiol. Infect. Dis. 4:95-107.
10. Hardy, D. J., R. N. Swanson, R. A. Rode, K. Marsh, N. L. Shipkowitz and J. J. Clement. 1990. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob. Agents Chemother. 34:1407-1413.
11. Jorgensen, J. H. 1992. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin. Infect. Dis. 14:1119-1123.
12. 11a. Jorgensen, J. H. Personal communication.
13. Jorgensen, J. H., G. V. Doern, L. A. Maher, A. W. Howell, and J. S. Redding. 1990. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 34:2075-2080.
14. Jorgensen, J. H., J. S. Redding, L. A. Maher, and A. W. Howell. 1987. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J. Clin. Microbiol. 25:2105-2113.
15. Juteau, J., and R. C. Levesque. 1990. Sequence analysis and evolutionary perspectives of ROB-1 β-lactamase. Antimicrob. Agents Chemother. 34: 1354-1359.
16. Khan, W., S. Ross, W. Rodriguez, G. Controni, and A. K. Saz. 1974. Haemophilus influenzae type b resistant to ampicillin: a report of two cases. JAMA 229:298-301.
17. Malouin, F., A. B. Schryvers, and L. E. Bryan. 1987. Cloning and expression of genes responsible for altered penicillin-binding proteins 3a and 3b in Haemophilus influenzae. Antimicrobial. Agents Chemother. 31:286-291.
18. Markowitz, S. M. 1980. Isolation of an ampicillin-resistant, non-β-lactamase-producing strain of Haemophilus influenzae. Antimicrob. Agents Chemother. 17:80-83.
19. Medeiros, A. A., R. Levesque, and G. A. Jacoby. 1986. An animal source for the ROB-1 β-lactamase of Haemophilus influenzae type b. Antimicrob. Agents Chemother. 29:212-215.
20. Mendelman, P. M., D. O. Chaffin, T. L. Stull, C. E. Rubens, K. D. Mack, and A. L. Smith. 1984. Characterization of non-β-lactamase-mediated ampicillin resistance in Haemophilus influenzae. Antimicrob. Agents Chemother. 26: 235-244.
21. Montgomery, K. L., L. Raymundo, Jr., and W. L. Drew. 1979. Chromogenic cephalosporin spot test to detect beta-lactamase in clinically significant bacteria. J. Clin. Microbiol. 9:205-207.
22. National Committee for Clinical Laboratory Standards. 1995. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. M7-A4. National Committee for Clinical Laboratory Standards. Villanova, Pa.
23. Parr, T. R., Jr., and L. E. Bryan. 1984. Mechanism of resistance of an ampicillin-resistant, β-lactamase-negative clinical isolate of Haemophilus influenzae type b to β-lactam antibiotics. Antimicrob. Agents Chemother. 25:747-753.
24. Rittenhouse, S. F., L. A. Miller, R. L. Kaplan, G. H. Mosely, and J. A. Poupard. 1995. A survey of β-lactamase-producing Haemophilus influenzae. Diagn. Microbiol. Infect. Dis. 21:223-225.
25. Rubin, L. G., R. H. Yolken, A. A. Medeiros, and E. R. Moxon. 1981. Ampicillin treatment failure of apparently β-lactamase-negative Haemophilus influenzae type b meningitis due to novel β-lactamase. Lancet i:1008.
26. Scriver, S. R., D. E. Low, A. E. Simor, B. Toye, A. McGeer, R. Jaeger, and Canadian Haemophilus Study Group. 1992. Broth microdilution testing of Haemophilus influenzae with Haemophilus Test Medium versus lysed horse blood broth. J. Clin. Microbiol. 30:2284-2289.
27. Scriver, S. R., S. L. Walmsley, C. L. Kau, D. J. Hoban, J. Brunton, A. McGeer, T. C. Moore, E. Witwicki, Canadian Haemophilus Study Group, and D. E. Low. 1994. Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their β-lactamases. Antimicrob. Agents Chemother. 38:1678-1680.
28. Tomeh, M. O. S. E. Starr, J. E. McGowan, Jr., P. M. Terry, and A. J. Nahmias. 1974. Ampicillin-resistant Haemophilus influenzae type b infection. JAMA 229:295-297.
29. Tremblay, L. D., J. L'Ecuyer, P. Provencher, M. G. Bergeron, and Canadian Study Group. 1990. Susceptibility of Haemophilus influenzae to antimicrobial agents used in Canada. Can. Med. Assoc. J. 143:895-901.